Why Trials Fail: Timing as a Design Variable: A systems-level critique of randomized trial design

Trial failure is not always a failure of biology.It is often a failure of timing built into trial design.When time is ignored, evidence can miss when treatments actually work. Randomized controlled trials are designed to determine whether a treatment works. When trials fail, the result is usually interpreted as evidence that the mechanism, target, or molecule is incorrect. This paper proposes a different interpretation: that a substantial fraction of trial failure reflects structural blindness to timing. From a systems-dynamic perspective, disease is not a stable state but a process that evolves through phases with differing responsiveness. Treatment effect is therefore not fixed, but depends on when an intervention meets the system. Classical trial design does not account for this temporal structure. Instead, it treats timing as logistics rather than as a biological variable. The paper identifies four structural points where timing is lost in trial design: inclusion criteria that ignore phase, fixed endpoints that do not align with system response, averaging methods that erase temporal variation, and wash-out periods that are not interpreted as diagnostic data. Together, these features can systematically obscure phase-dependent treatment effects and produce negative or inconclusive results even when an intervention is biologically relevant. Trial failure is reframed not only as a biological outcome, but as a design outcome. Negative results may reflect that an intervention was tested in a population without remaining plasticity, measured outside its response window, or evaluated in a way that removes temporal structure. This work is part of the Timing & Failure series and builds on previous papers that examine treatment failure and clinical interpretation from a systems perspective. Rather than proposing new technologies, the paper introduces a shift in perspective: timing should be treated as a central design variable in clinical trials. Making time visible in trial design allows evidence to capture not only whether an intervention works, but when it can work.